The chemokine receptor CCR5 acts as an essential cofactor for cell entry by macrophage-tropic human immunodeficiency virus type 1 (HIV-1) strains, whereas CXCR4 acts as an essential cofactor for T-cell-line-adapted strains. We demonstrated that the specific amino acids in the V3 loop of the HIV-1 envelope protein that determine cellular tropism also regulate chemokine coreceptor preference for cell entry by the virus. Further, a strong correlation was found between HIV-1 strains classified as syncytium inducing in standard assays and those using CXCR4 as a coreceptor. These data support the hypothesis that progressive adaptation to additional coreceptors is a key molecular basis for HIV-1 phenotypic evolution in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC192016 | PMC |
| http://dx.doi.org/10.1128/JVI.71.9.7136-7139.1997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.
PLoS Med
January 2025
Division of Infectious Diseases, Department of Medicine II, Medical Centre and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Background: Self-reported health problems following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are common and often include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The long-term prognosis of such post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) is unknown, and data finding and correlating organ dysfunction and pathology with self-reported symptoms in patients with non-recovery from PCS is scarce. We wanted to describe clinical characteristics and diagnostic findings among patients with PCS persisting for >1 year and assessed risk factors for PCS persistence versus improvement.
View Article and Find Full Text PDFComparative- and Cost-Effectiveness Research Determining the Optimal Intervention for Advancing Transgender Women With HIV to Full Viral Suppression (Text Me, Alexis!): Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
January 2025
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.
Background: Many transgender women with HIV achieve suboptimal advancement through the HIV Care Continuum, including poor HIV health care usage, retention in HIV medical care, and rates of viral suppression. These issues are exacerbated by comorbid conditions, such as substance use disorder, which is also associated with reduced quality of life, increased overdose deaths, usage of high-cost health care services, engagement in a street economy, and cycles of incarceration. Thus, it is critical that efforts to End the HIV Epidemic include effective interventions to link and retain transgender women in HIV care through full viral suppression.
View Article and Find Full Text PDFResearch progress of femoral head necrosis in HIV-infected patients.
Ann Med
December 2025
Department of Joint and Sports Medicine, Zhongnan Hospital, Wuhan University, Wuhan, China.
As life expectancy among patients infected with the human immunodeficiency virus (HIV) increases, a growing number of complications have been observed. This population displays an elevated risk of ischemic necrosis of the femoral head in comparison to the general population, which may be attributed to HIV infection, antiretroviral medication use, and hormone application. Patients infected with the human immunodeficiency virus (HIV) who also have necrosis of the femoral head tend to present at an earlier age, with a rapid disease progression and a high incidence of bilateral onset.
View Article and Find Full Text PDFCommunity prevalence of blood-borne viruses (hepatitis B and HIV) in Ireland.
Ir J Med Sci
January 2025
Sligo University Hospital, Sligo, Ireland.
Background: Chronic infection with hepatitis B virus and HIV causes significant morbidity and mortality. Effective antiviral treatment is available for both. Ireland has historically been considered a low prevalence country.
View Article and Find Full Text PDFInterest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs.
J Addict Med
January 2025
From the Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA (EPB, JIT); Department of Public Health Sciences, Clemson University, Clemson, SC (MH, SSL); School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada (LBS); Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (SM); Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA (PL); Department of Pharmacy Practice and Clinical Research, University of Rhode Island, Kingston, RI (LET); West Virginia University School of Medicine, Morgantown, WV (JF); Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA (AK); Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY (BN); Department of Psychology, Clemson University, Clemson, SC (IP-V); University of New Mexico Health Sciences Center, Department of Internal Medicine, University of New Mexico, Albuquerque, NM (KP); and Department of Medicine, University of South Carolina School of Medicine, Greenville, SC (AHL).
Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!